Novartis

Novartis discovers and develops human medicines, generic pharmaceuticals, over-the-counter and animal health products. Read more

105,578 Followers on Owler
105,578 Followers on Owler
105,578 Followers on Owler
105,578 Followers on Owler

Novartis

Novartis discovers and develops human medicines, generic pharmaceuticals, over-the-counter and animal health products. Read more

Vasant Narasimhan's photo - CEO of Novartis

CEO

Vasant Narasimhan

CEO Approval Rating

72/100

Founded:

1996

Status:

PublicIndependent CompanyNYSENVS

NOVARTIS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Pfizer is the top competitor of Novartis. Pfizer is a Public company that was founded in New York, New York in 1849. Like Novartis, Pfizer also operates in the Pharmaceuticals sector. Pfizer has 39,893 fewer employees vs. Novartis.

Merck is seen as one of Novartis's biggest rivals. Merck was founded in Kenilworth, New Jersey} in 1891. Like Novartis, Merck also competes in the Pharmaceuticals space. Compared to Novartis, Merck generates $1.9B less revenue.

BMS is perceived as one of Novartis's biggest rivals. BMS was founded in 1858, and is headquartered in New York, New York. Like Novartis, BMS also operates in the Pharmaceuticals space. BMS generates $7.1B less revenue vs. Novartis.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Cipla a competitor of Novartis?

Novartis Quarterly and Annual Revenue

Coming soon for Novartis!

Annual Revenue

$49.9B

Novartis's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 32.2B.

Novartis Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Cadent Therapeutics, Inc.

Dec 2020

Source »
$210M
Cadent Therapeutics is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of neurological diseases.
Vedere Bio, Inc.

Oct 2020

Source »
$150M
Vedere Bio is a biopharmaceutical company that researches and develops ocular gene therapies for the treatment of eye disorders.
Amblyotech, Inc.

Apr 2020

Source »
undisclosed
Amblyotech is a therapeutics firm that provides treatments for amblyopia and ocular disorders.
The Medicines Company

Nov 2019

Source »
$9.7B
The Medicines Company is a biopharmaceutical company that researches and develops therapeutics for the treatment of cardiovascular diseases.

-

IFM Due, IFM Therapeutics

Sep 2019

Source »
undisclosed
-

These are all the companies that Novartis has acquired. Novartis has acquired 20 companies and its latest acquisition was Cadent Therapeutics, Inc. in Dec 2020. Cadent Therapeutics is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of neurological diseases.

Novartis Funding History

No recent funding data found related to Novartis

Novartis Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Aktis is a Massachusetts-based biotechnology firm that develops and commercializes radiopharmaceuticals for the treatment of cancer.
$72M
Mar 17, 2021
Series A
-
Credence MedSystems is a medical device company that produces and supplies injectable drug delivery devices for the pharmaceutical industry.
-
Jan 25, 2021
Corporate Round
-
Pear Therapeutics is a prescription digital therapeutic platform that offers clinical engagement and patient tracking solutions for clinicians.
$80M
Dec 06, 2020
Series D
-
Mekonos is a biotechnology firm that develops and commercializes SoC-based gene-editing systems for the pharmaceutical industry.
$4.6M
Nov 23, 2020
Venture Round
-
Koneksa Health develops a digital biomarker platform that offers patient-generated data capturing, monitoring and analyzing solutions.
$16M
Sep 27, 2020
Series B
-

These are all the companies that Novartis has invested in. Novartis has invested 20 companies and its latest investment was Cadent Therapeutics, Inc. in Dec 2020. Cadent Therapeutics is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of neurological diseases.

Novartis News

May 4, 2021FierceBiotechIT

Novartis loses 2nd oncology R&D exec as Hammerman leaves through the door left open by Engelman

Novartis loses 2nd oncology R&D exec as Hammerman leaves through the door left open by Engelman badam... See more »
May 3, 2021Global Legal Chronicle

Alcon's Acquisition of U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza

Skadden, Arps, Slate, Meagher & Flom LLP advised Alcon on the deal. Alcon, the global leader in eye c... See more »
April 28, 2021PMLiVE

Novartis announces delay in UK cholesterol drug study

The delay was caused by recruitment issues during the COVID-19 pandemic... See more »
April 28, 2021MarketScreener

ESG Update - April 28, 2021 (PDF 0.3 MB)

(marketscreener.com) Q1 2021 ESG Update for investors and analysts April 28, 2021 Dear investors and ... See more »
April 27, 2021Investor’s Business Daily

Novartis Generics Face 'Challenging Quarter,' But Gene Therapy Shines

Revenue from Novartis gene therapy Zolgensma surged in the first quarter, but Novartis stock fell on ... See more »

Novartis Blogs

March 3, 2021Novartis Blog

Teaching a daughter the power of purpose

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including thro... See more »
March 3, 2021Novartis Blog

Challenging a young scientist to focus on patients

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including thro... See more »
January 20, 2021Novartis Blog

Digital innovation looks set to dominate the 2021 healthcare agenda

COVID-19 was a catalyst for change in healthcare during 2020 - an accelerator for digital health.2021... See more »
December 15, 2020Novartis Blog

AI Nurse evolving for health failure patients in China

Dozens of improved versions of our new digital platform for heart failure disease management in China... See more »
November 24, 2020Novartis Blog

Turning the sound up on patient voices in lung cancer research and development

For Pierre-Alexis Ruffié, managing clinical trials at Novartis is personal. "I don't usually s... See more »
November 17, 2020Novartis Blog

Predictive analytics could bring medicines to patients faster

Before leaving port, sailors rely on meteorological data - wind force, swell, air temperature - to he... See more »
November 17, 2020Novartis Blog

Take a visual tour of medicines that target RNA

Cells have a built-in search and delete function. The existence of such a system came as a surprise 3... See more »

Novartis Press Releases

February 4, 2021Accesswire

Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro

- New study shows that Molecular Partners' tri-specific antiviral DARPin® candidates, ensovibep (MP04... See more »
January 29, 2021NewsFile

Investigation of iRhythm Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - January 29, 2021) - Holzer & Holzer, LLC is investigating whether... See more »
October 21, 2020Cision Canada

Novartis in Canada driving digital healthcare solutions with the inauguration of a Biome innovation hub

/CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. announced today the launch of the Novartis Canada... See more »
October 15, 2020Cision Canada

Health Canada approves first-ever gene replacement therapy, Luxturna

/CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has app... See more »
August 27, 2020PR Newswire

Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper

/PRNewswire/ -- Novartis announced today, in honor of National Psoriasis (PsO) Awareness Month, Gramm... See more »
August 17, 2020Cision Canada

16th annual Novartis Ride for Life goes virtual to raise funds for cancer research

/CNW Telbec/ - The 16th annual Novartis Ride for Life has been converted to a new format this year d... See more »

Novartis Videos

December 12, 2019Novartis Youtube Channel

"Next Generation Scientist 2019" on YOUTUBE

November 25, 2019Novartis Youtube Channel

"The Power of Purpose - Clare's story" on YOUTUBE

September 18, 2019Novartis Youtube Channel

"Without Genevieve..." on YOUTUBE

September 18, 2019Novartis Youtube Channel

"Meet Valentina" on YOUTUBE

Social Media

Novartis Headquarters

Lichtstrasse 35

Basel, Basel-City4056

41-61-324-0000

Driving Directions »

Trending Companies

Novartis Summary

ABOUT

Overview

Novartis AG (NYSE: NVS) discovers and develops eye care, generics, vaccines, and over-the-counter medicines. Novartis is a global healthcare company based in Basel, Switzerland that provides solutions to the evolving needs of patients worldwide. The f...

CEO

Novartis's CEO, Vasant Narasimhan, currently has an approval rating of 72%. Novartis's primary competitors are Pfizer, Merck & BMS.

Website

novartis.com

Frequently Asked Questions about Novartis

  1. When was Novartis founded?

    Novartis was founded in 1996
  2. Who is Novartis's CEO?

    Novartis's CEO is Vasant Narasimhan
  3. How much revenue does Novartis generate?

    Novartis generates $49.9B in revenue
  4. How much funding does Novartis have?

    Novartis has historically raised $0 in funding
  5. Where is Novartis's headquarters?

    Novartis's headquarters is in Basel Basel-City, CH
  1. How many employees does Novartis have?

    Novartis has 118,393 employees
  2. What sector does Novartis operate in?

    Novartis is in Pharmaceuticals
  3. Who are Novartis's competitors?

    Novartis's top competitors are Pfizer, Merck, BMS
  4. Who has Novartis invested in?

    Novartis's has invested in companies such as Aktis Oncology, Credence, Pear Therapeutics